News Hub | News Direct

All Industries


Article thumbnail News Release

MedCognetics Secures Groundbreaking Patent for Inclusive, Unbiased Medical Imaging AI Technology in Mammography

MedCognetics

In a significant stride towards equitable healthcare technology, MedCognetics, Inc., a company focusing on medical imaging AI, today announced it has been awarded patent number 11,948,297 by the United States Patent and Trademark Office (USPTO). The patent covers architectural strategies and methodologies for achieving unbiased AI in breast imaging. This innovation is backed by MedCognetics’ peer-reviewed publications in industry conferences such as the Radiological Society North America (RSNA) 2023, the European Society of Radiology (ESR) 2024, and a grant from the National Institutes of Health (NIH). This breakthrough is set to redefine the development of AI in the medical field ensuring MedCognetics’ algorithms maintain high performance across different patient demographics, thereby guaranteeing consistent, fair, superior patient outcomes. "This patent is a reflection of our team's focused pursuit of innovation and commitment to inclusivity,” said Ron Nag, CEO of MedCognetics, Inc. “Our technology is not just about improving patient outcomes through earlier and more accurate diagnoses; the focus is on fostering equality in technological development and ensuring universal access to advancements in healthcare systems worldwide. We remain dedicated to progressing in the field of unbiased medical imaging technology.” MedCognetics is actively engaged in partnerships with leading healthcare institutions and research organizations to bring its patented AI technology into clinical practice, aiming for widespread patient benefit from these advancements at the earliest. Full details of the allowance are listed in the Issue Notification Certificate issued by the USPTO. For further information about MedCognetics and its pioneering medical imaging AI technology, please visit www.medcognetics.com. About MedCognetics, Inc. MedCognetics provides an advanced AI software platform that integrates into radiology workflow. In addition, the AI algorithm is trained on a diverse global patient dataset to mitigate data biasing. The future of AI in healthcare is unbiased services and MedCognetics is at the forefront of creating a more predictable medical outcome and ultimately saving lives. Founded in 2020, the company is based in Dallas, Texas. For more information, please visit our website at www.medcognetics.com. Contact Details ANW Networks Alicia Nieva-Woodgate +1 415-515-0866 alicia@anwnetworks.com Company Website https://www.medcognetics.com

April 03, 2024 11:30 AM Eastern Daylight Time

Article thumbnail News Release

Nextech3D.ai protects intellectual property with a patent for generating 3D models from 2D images

Nextech3D.AI

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce a significant milestone for the company as the U.S. Patent and Trademark Office (USPTO) officially issued a patent for their technology to generate three-dimensional models from two-dimensional images. Gappelberg emphasized the importance of this patent in the realm of artificial intelligence (AI) and 2D to 3D model generation, describing it as a pivotal patent for the 3D modeling industry. He highlighted that this patent adds substantial value to Nextech3D.ai and positions the company as one of the technology leaders in the field of converting 2D photos to 3D models using AI. The issuance of this patent provides Nextech3D.ai with a competitive advantage, setting them apart from other companies involved in 3D model generation. Gappelberg expressed confidence that this patent, along with a second AI patent issuance and seven additional patents filed, strengthens the company's position and builds a moat around their 3D model-making business for e-commerce. With a focus on both industry expertise and intellectual property, including GPT AI-powered 3D model generation, Nextech3D.ai aims to increase shareholder value by investing in 3D-AI GPT patents and solutions. Gappelberg emphasized that this second AI patent approval reinforces and validates the company's commitment to innovation and generating substantial revenue through 3D modeling. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

April 03, 2024 11:20 AM Eastern Daylight Time

Video
Article thumbnail News Release

First Phosphate 2nd set of assays at Begin-Lamarche shows 2 metre vein of massive Apatite

First Phosphate Corp

First Phosphate Corp CEO John Passalacqua and Chief Geologist Gilles Laverdiere joined Steve Darling from Proactive to provide an update on the company's 25,000-meter drill program at the Bégin-Lamarche project in Quebec. So far, the company has drilled 16,435 meters, with assays back from 5,642 meters. Passalacqua explained to Proactive that drilling at the Phosphate Mountain Zone continues to deliver strong phosphate mineralization. Both the Mountain and Northern Zones exhibit high-grade phosphate on the surface, while the Southern Zone shows large tonnage potential over a strike length of 1.5 kilometers. At the Phosphate Mountain Zone: Drill hole BL-24-48 intersected 15.01% P2O5 (phosphate) over 7.65 meters from a depth of 36.9 meters, including one assay of 31.24% P2O5 over 1.1 meters. Other drill holes in this zone also yielded core results of 30%+ apatite. The Northern Zone included drill hole BL-24-36 intersected 6.83% P2O5 over 108.0 meters starting at a depth of 234.0 meters. Drill hole BL-24-44 intersected 7.48% P2O5 over 90.6 meters starting at a depth of 192.4 meters. At the Northwestern Zone drill hole BL-24-49 intersected 8.65% P2O5 over 33.0 meters from a depth of 72.5 meters while the Southern Zone showed drill hole BL-24-43 intersected 5.41% P2O5 over 258.0 meters from a depth of 111.0 meters. These results demonstrate the significant phosphate potential of the Bégin-Lamarche project, reaffirming the company's commitment to advancing its exploration efforts in the region. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

April 03, 2024 10:25 AM Eastern Daylight Time

Video
Article thumbnail News Release

Gaming Realms reports record 2023, driven by strong content licensing growth

Gaming Realms PLC

Gaming Realms PLC (AIM:GMR, OTCQX:PSDMF) CEO Mark Segal discusses the company's record-breaking results for 2023 in an interview with Proactive's Stephen Gunnion. The firm witnessed a 26% increase in top-line revenue, reaching £23 million, predominantly fuelled by a 33% growth in its content licensing business, which accounted for £19 million. This expansion was driven by the company's entry into new markets and the introduction of 44 new partners over the year, alongside the launch of innovative games. Gaming Realms' Slingo portfolio led the charge, and it licensed games such as a Tetris-themed game and Space Invaders, leveraging classic video game IPs. Its portfolio of proprietary games expanded to 75, further diversifying its offering. The company also marked its presence in new territories, including West Virginia, Sweden, Greece, and notably Portugal, where it launched in the last quarter of the previous year with positive results. The US emerged as its top market, showing growth of 22%, with the company live in several states and plans to expand into West Virginia. Gaming Realms experienced a significant increase in unique users, exceeding 5 million, with a notable 33% rise in licensing revenue, much of which came from existing partners at the start of 2023. The UK and Canada were highlighted as key markets, with substantial growth observed, particularly in Canada's newly regulated Ontario market and Italy. Looking forward, Segal remains optimistic about 2024, with licensing income already up by 20% in the first two months. The momentum gained since 2019, transitioning from a loss in that year to over £10 million in adjusted EBITDA in 2023, is expected to continue, driven by the compounding effect of new partnerships. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 03, 2024 10:17 AM Eastern Daylight Time

Video
Article thumbnail News Release

ARway.ai sees positive results from deployment of AR wayfinding at campus of Brandenburg University

ARway.ai

ARway.ai Chief Product Officer Shadnam Khan joined Steve Darling from Proactive to unveil the successful deployment of an innovative AR navigation system within the 5G campus network built by Deutsche Telekom AG at the Brandenburg University of Applied Sciences campus in Germany. The fully funded partnership with the Brandenburg University of Applied Sciences and its prestigious institute ifii (Institute for Innovation and Information Management), originally announced in October 2023, revolutionizes the way faculty and visitors experience the university campus. It provides a seamless and intuitive AR experience and AR-powered navigation. As part of their 2024 roadmap, the university will implement, evaluate, and publish research on over 20 different use cases with ARway's technology, highlighting the depth of this collaboration. Khan emphasized that a significant number of master's students are conducting their theses on AR, leveraging the new system for their research. This academic involvement underscores the system's role not only as a navigational tool but also as a platform for academic and technological exploration. The company anticipates that this project will set new standards for digital campus experiences and open new pathways for the application of AR and 5G technologies in various sectors. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

April 03, 2024 10:14 AM Eastern Daylight Time

Video
Article thumbnail News Release

HEALWELL AI shares major company milestones since its debut in Q4 of 2023

HEALWELL AI Inc.

HEALWELL AI CEO Dr. Alex Dobranowski joined Steve Darling from Proactive to provide a corporate update, including the release of preliminary financial results for its Fiscal Fourth Quarter and Year Ended December 31, 2023. HEALWELL AI, which debuted in the fourth quarter of 2023, has achieved significant milestones since its inception. HEALWELL successfully raised approximately $29.5 million, providing the company with significant financial resources to fuel its growth initiatives. HEALWELL completed the acquisition of a majority interest in Pentavere, an AI healthcare company. This acquisition enhances HEALWELL's capabilities and strengthens its position in the healthcare AI market. HEALWELL announced a partnership with WELL Health Technologies, whereby WELL Health adopted HEALWELL's AI-powered physician co-pilot product, WELL AI Decision Support. This marks a significant milestone in the adoption of HEALWELL's technology in the healthcare industry. HEALWELL announced the acquisition of Intrahealth, an enterprise-class Electronic Health Record (EHR) company. This acquisition has contributed to HEALWELL's yearly run-rate revenues, which now exceed $20 million, primarily driven by SaaS and services. Dobranowski expressed optimism about HEALWELL's outlook, citing its organic growth profile and M&A strategy. The company has a strong and active acquisition pipeline, with the potential to more than double its current revenue run-rate to over $40 million per year using existing cash on hand. HEALWELL's strategic alliance with equity investor WELL Health Technologies continues to flourish, with significant activity in both Canada and the United States. In Canada, WELL Health recently launched WELL AI Decision Support, an AI-powered physician co-pilot providing clinical decision support for rare disease diagnosis and preventative care, sourced entirely from HEALWELL. Overall, HEALWELL AI is well-positioned for continued growth and success in the dynamic healthcare AI market, leveraging its innovative technology, strategic partnerships, and robust acquisition strategy. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 03, 2024 10:07 AM Eastern Daylight Time

Video
Article thumbnail News Release

PathAI Announces Research Presentations at the 2024 AACR Annual Meeting

PathAI

PathAI, Inc., a leading AI-powered precision pathology company, today announced it will present research from its portfolio of oncology products at the AACR Annual Meeting on April 7-10, 2024, in San Diego, CA. The research demonstrates how machine learning models developed to characterize the tumor microenvironment (TME) from routine hematoxylin and eosin (H&E)-stained whole slide images (WSIs) can be used to advance biomarker development and precision medicine strategies. The presentations include new research leveraging PathAI’s pan-tumor foundation models and its commercially available product, PathExplore 1, to identify key histologic features associated with molecular signatures and patient response to therapy. Highlights: Researchers deployed PathExplore on HNSCC and NSCLC samples to characterize the cell and tissue composition of the tumor microenvironment, as well as compute immune phenotypes directly from H&E WSI. (Poster #905 ) Researchers from Incendia Therapeutics developed a continuous scoring method for Discoidin Domain Receptor 1 (DDR1), which revealed widespread immune exclusion in tumors based on the spatial distribution of lymphocytes, CD8+ T cells, and CD45+ immune cells from H&E and mIF images. DDR1 is highly expressed in epithelial cancers and has been implicated in tumor growth, invasion, and lack of response to therapy. The immune exclusion score correlates with DDR1 mRNA and protein expression. The study provides additional insight into the role of DDR1 in human cancers and may be useful in selecting indications and stratifying patients for DDR1-targeted therapies. (Poster #2916 ) Using unsupervised learning driven by PathExplore’s features and a novel collagen fiber detection imaging technology, researchers discovered three distinct phenotypes of cancer associated stroma (CAS) that had distinct patterns of association with survival and gene expression signatures. Two of them were enriched in collagen fiber density as well as in density of fibroblasts, while the third phenotype had the highest density of immune cells, providing a categorization of different types of CAS-tumor interaction that may be useful for patient stratification. (Poster #4912 ) Using AI-powered models from PathAI, Foundation Medicine researchers investigated digital pathology TME features of immunotherapy outcomes among NSCLC patients within a real-world dataset from the Flatiron Health-Foundation Medicine Clinico-Genomic Database. These results indicate that the composition of the TME assessed via digital pathology may have utility in identifying NSCLC patients who will respond to first-line immune checkpoint inhibitors beyond the established immunotherapy biomarkers. (Poster #4969 ) In collaboration with EMD Serono, AI-powered TME models from PathAI were used to analyze H&E WSI of NSCLC from a randomized Phase 3 trial directly comparing two immunotherapies. Researchers compared cell abundance features with gene expression data from the same samples and found that immune and stromal cell abundance features were associated with expression of genes in relevant cellular pathways, confirming the biological relevance of our cellular features. In analyzing the features alongside the clinical data from the retrospective study, researchers identified candidate prognostic immunotherapy biomarkers. (Poster #6179 ) Researchers from Incendia Therapeutics illustrated that morphologic features derived from H&E images using PathExplore can be effective predictors of CD8-defined immune exclusion, providing an option for patient stratification by immune phenotype using widely available H&E images. The features and direction of association align with prior knowledge of the mechanism or manifestations of immune exclusion or infiltration in the TME, including the relative density of lymphocytes in tumor and stroma. (Poster #7392 ) PathAI’s pan-tumor foundation models were used to identify tissue regions and cell types on H&E WSI to quantify tumor purity across multiple tumor types. Model-derived tumor purity estimates were compared to three orthogonal molecular methods of purity and found to correlate across disease indications. These results provide evidence of how AI can improve the efficiency of molecular testing and enhance precision diagnostic strategies. (Poster #7402 ) Follow PathAI on LinkedIn and X for more updates from #AACR24 and visit us in person at booth #1549. 1 PathExplore is For Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

April 03, 2024 10:00 AM Eastern Daylight Time

Article thumbnail News Release

ETHICAL SEARCH ENGINE KARMA ARRIVES IN THE U.S.; EMPOWERS USERS TO PROTECT ANIMALS AND BIODIVERSITY BY BROWSING THE WEB

KARMA

KARMA, the world’s first search engine dedicated to protecting animals and biodiversity, is now available in the United States. KARMA utilizes the revenue generated by users’ Internet searches to fund its first non-profit partners, Re:wild and Humane Society International, expected to surpass $100M in [the United States/North America] over the next three years. KARMA taps into the sponsored links market – worth a whopping $300+ billion per year – to help fund rigorously selected non-profit partners recognized for their actions in animal protection and biodiversity conservation. Similar to traditional search engines, KARMA displays sponsored links when users make an online search. However, unlike traditional search engines, KARMA donates 100% of its proceeds to its non-profit partners. Launched in France in 2022, KARMA has received enthusiastic feedback, with more than 150,000 downloads and rave user reviews, averaging a rating of 4.7 stars across the leading app stores. KARMA was also recently selected by Google to be displayed in the Google Choice Screen menu in European markets. As a result, Android users are prompted during setup to choose their default search engine among a list of 12 options that now includes KARMA. The ongoing antitrust case from the U.S. government against Google may also lead to a similar development coming to U.S. markets in the future. With an estimated market size of $132B, the U.S. sponsored links market segment is highly lucrative and a tremendous opportunity for KARMA and its cause. “Search engines are used daily by all Internet users, making them the most scalable of tools capable of having a material impact in supporting financially the urgent needs of animal protection and biodiversity conservation, said Yann Kandelman, Co-Founder and CEO of KARMA. “KARMA is providing Internet users with the opportunity to be part of the solution in just a few clicks. For example, if just 1% of Google users were to use KARMA as their default search engine, we would be able to donate more than $1 billion per year to our non-profit beneficiaries, including our first selected partners, Re:wild and Humane Society International.” Learn & Act with KARMA In a world where a species becomes extinct every 20 minutes and animal suffering is at an all-time high thanks, in part, to 99% of U.S. meat coming from factory farms, KARMA also pledges to empower its users to “Learn & Act.” "Thanks to its "Learn & Act" feature, KARMA provides a news feed of useful information and highlights concrete and easy ways to make a difference on a daily basis. In just a few clicks, users can maximize their impact by signing a petition, registering to try a vegan diet for a week, participating in a citizen science project to identify bird species in their area, and more. More on KARMA’s Partnership with Re:Wild and Humane Society International KARMA has selected Re:wild and Humane Society International-two key players in the biodiversity conservation and animal protection movements- as its first two non-profit partners. The organizations have joined forces with KARMA and will benefit from the $100M KARMA expects to raise in the North America over the next 3 years. “Conserving biodiversity is not just about saving individual species,” said Carrie Hutchison, director of marketing and brand for Re:wild. “It’s about maintaining the complex ecosystems that sustain life on Earth. By working with companies like KARMA, which are supporting our conservation work and expanding our reach, we can protect more of the world’s irreplaceable places for biodiversity, and inspire a global community to act for the wild.” “At Humane Society International, we believe in creating a world where animals are treated with respect and protected from cruelty. Switching your default search engine to KARMA is an easy and free way to support our work. Your internet searches with KARMA can help fund our vital initiatives such as banning the sale of real fur, ending some of the most inhumane factory farming practices, and creating a more compassionate world for all animals,” said Nick Jones, executive director at Humane Society International/UK. KARMA is exploring future partnerships with several other American nonprofits using complementary levers to protect animals and biodiversity. Robust, Versatile and Privacy-Friendly: The Technology Behind Karma KARMA is available on all platforms: through a mobile browser app on iOS and Android, and through an extension for Chrome, Safari, Brave, Firefox and Edge on both PC and Mac. KARMA technology makes it a robust, transparent, and secure search engine: Based on privacy-oriented search engine Brave Search, KARMA’s web indexing is fully independent from internet giants Google and Bing, making it an ethical alternative, alongside other challengers launched in the recent years (Perplexity.ai, You.com, PreSearch, Yep, etc.), in a market traditionally dominated by large, listed companies. Developed based on Firefox’s open-source code, KARMA’s mobile application supports ad blockers and anti-tracking extensions. To ensure the best results to users, KARMA provides a one-click access to a wide range of vertical, independent search engines: unbiased customer reviews from Reddit, royalty-free images from Unsplash, GIFs from GIPHY, etc. Committed to protecting their users’ privacy, KARMA does not permanently store search histories nor resell personal data to third parties. Additional KARMA photos and imagery may be found here: About KARMA KARMA is the first alternative search engine dedicated to protecting animals and biodiversity. Unlike traditional search engines, KARMA empowers users to make a tangible impact on the planet without changing their browsing habits. By simply utilizing KARMA for their internet searches, individuals contribute to fund nonprofits safeguarding wildlife, promoting animal welfare and preserving biodiversity worldwide. About Re:wild Re:wild has a singular and powerful focus: the wild as the most effective solution to the interconnected climate, biodiversity and human wellbeing crises. Founded by a group of renowned conservation scientists together with Leonardo DiCaprio, Re:wild is a force multiplier that brings together Indigenous peoples, local communities, influential leaders, nongovernmental organizations, governments, companies and the public to protect and rewild at the scale and speed we need. About Humane Society International Advancing the welfare of animals in more than 50 countries, Humane Society International works around the globe to promote the human-animal bond, rescue and protect dogs and cats, improve farm animal welfare, protect wildlife, promote animal-free testing and research, respond to disasters and confront cruelty to animals in all of its forms. Contact Details Becker PR for KARMA Eric Becker +1 303-638-3469 press@mykarma.org

April 03, 2024 10:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Analyst Crypto Jebb Urges To Buy Ethereum Right Now! Cardano Left in the Dust As KangaMoon Bull Run Continues!

Kangamoon

Renowned analyst Crypto Jebb has been talking about Ethereum (ETH) a lot lately and people are starting to listen. Meanwhile, Cardano (ADA) has been outshined by many altcoins like KangaMoon (KANG), which is on a massive bull run. This Stage 5 presale star has already provided early buyers with 291% ROI, causing many experts to hint at a $0.5 price in 2024. Crypto Jebb: Ethereum Price Will Moonshot Recently, Ethereum (ETH) has been on an uptrend. Over the past 30 days, the Ethereum price soared from $3,409 to $3,557. During that time, its market cap increased from $410B to $427B. According to crypto analyst Crypto Jebb, this bullish trend will continue for the Ethereum crypto. He forecasts a potential 10x on ETH within the next ten years. This altcoin's technical analysis also shows a bullish future. For instance, Ethereum is now trading above its 100— and 200-day EMAs. Additionally, 25 technical indicators are showing green for ETH. As a result, experts have made a bullish Ethereum price prediction. They foresee this altcoin's price hitting $4,489 within Q2 of 2024. Cardano (ADA): Trading in the Red On the other hand, Cardano (ADA) has been trading in the red. According to CoinMarketCap data, the Cardano price sank from $0.73 to $0.63 over the past month. In that period, its market cap also fell from $26B to $22.46B. However, the technical analysis for this altcoin paints a different picture. Notably, the Cardano coin is trading above its 100 and 200-day EMAs. Additionally, this altcoin now has over 20 technical indicators showing bullish signs. Due to all these reasons, market analysts have made a bullish Cardano price prediction - a rise to $0.86 within Q2 of 2024. KangaMoon (KANG): Becoming One of the Altcoins To Watch While Ethereum and Cardano experience ups and downs, KangaMoon (KANG) has surfaced as an unexpected contender. This presale star has already soared by 291%, with 20,000 registered community members. Moreover, KangaMoon has raised over $3.9M and projects reaching $5M before April 2024 ends. Essentially, KangaMoon will develop a Play-to-Earn (P2E) game in which KANG will serve as the main in-game currency. With KANG, you can buy character upgrades or in-game items. Additionally, KANG holders gain exclusive access to challenges for extra tokens or in-game items. Another impressive part of KangaMoon is its dedication to cultivating an active community. As an example, users can earn free KANG tokens by being engaged members before the official launch. This has caused a significant surge in social media interaction as traders eagerly like, share and retweet KangaMoon's content. All these factors have helped KangaMoon obtain over 5,800 holders. Currently, one KANG token costs just $0.0196 - a 291% rise from its starting price of $0.005. Experts remain bullish as they forecast a rise to $0.5 once a Tier-1 CEX lists this altcoin in Q2 of 2024. This price prediction seems plausible with ties to the P2E gaming market, which will reach $885M by 2028. Will KangaMoon Rise Faster than Ethereum and Cardano? With its low $14M market cap, KangaMoon could outshine Ethereum and Cardano. This means it needs fewer new funds so the price can skyrocket faster. If you want to buy one of the top altcoins, sign up for its presale using the links below and get a 10% bonus. Discover the Exciting Opportunities of the KangaMoon (KANG) Presale Today! Website: https://Kangamoon.com/ Join Our Telegram Community: https://t.me/Kangamoonofficial Integrating GameFi and Play To EarnEmbark on your quest for glory. Assemble your champions, engage in epic battles or bet on your favorite fighters to earn $KANG tokens and exclusive rewards. Gain control of rare NFTs, unlock exclusive content and build alliances with fellow gamers as you ascend the ranks and leaderboards. Disclaimer: The following disclaimer is important to read and understand before engaging with Kangamoon, a play-to-earn meme coin. By accessing or participating in any activities related to Kangamoon, you acknowledge and accept the terms outlined below: 1 No Financial Advice: This whitepaper and any associated content do not constitute financial advice, investment recommendations, or solicitation to purchase Kangamoon tokens. The information provided is for informational purposes only. It is your responsibility to conduct thorough research and seek professional advice before making any financial decisions. 2 Volatility and Risks: Cryptocurrencies, including Kangamoon, are volatile and subject to significant price fluctuations. Investing in or holding Kangamoon tokens involves substantial risks, including the possibility of total loss. Past performance is not indicative of future results. 3 Regulatory Compliance: The regulatory environment surrounding cryptocurrencies is evolving and varies across jurisdictions. It is your responsibility to ensure compliance with applicable laws and regulations in your country or region before engaging with Kangamoon. 4 Uncertain Market: The market for meme coins and play-to-earn platforms is highly speculative and subject to rapid changes. There is no guarantee of market demand, liquidity, or utility for Kangamoon tokens. Token values may fluctuate drastically and may not reflect the intrinsic value of the project. By continuing to engage with Kangamoon, you acknowledge and accept the risks and limitations outlined in this disclaimer. You should only participate if you fully understand and are willing to assume these risks. Contact Details Kangamoon marketing@kangamoon.com Company Website https://kangamoon.com/

April 03, 2024 09:00 AM Central Daylight Time

Image
1 ... 437438439440441 ... 3897